Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26700966 | 0.95 | ALDH1A1 (0.46) | ALDH1A1TSHRLMNAKMT2ACYP3A4 | |
| SCHEMBL26700975 | 0.94 | CNR1 (0.47) | ALDH1A1TSHRLMNAKMT2ACYP3A4 | |
| SCHEMBL26700973 | 0.94 | CNR1 (0.47) | ALDH1A1TSHRLMNAKMT2ACYP3A4 | |
| SCHEMBL26700969 | 0.94 | HPGD (0.50) | ALDH1A1TSHRLMNAKMT2ACYP3A4 | |
| SCHEMBL24253269 | 0.87 | TSHR (0.47) | ALDH1A1TSHRLMNAKMT2ACYP3A4 | |
| SCHEMBL24725453 | 0.86 | HPGD (0.44) | ALDH1A1TSHRLMNAKMT2ACYP3A4 | |
| SCHEMBL25978308 | 0.85 | TSHR (0.51) | ALDH1A1TSHRLMNAKMT2ACYP3A4 | |
| SCHEMBL23484962 | 0.85 | FAAH (0.56) | ALDH1A1TSHRLMNAKMT2ACYP3A4 | |
| SCHEMBL23471810 | 0.84 | ALDH1A1 (0.50) | ALDH1A1TSHRLMNAKMT2ACYP3A4 | |
| SCHEMBL19155468 | 0.84 | TSHR (0.50) | ALDH1A1TSHRLMNAKMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227471-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227471-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, CBL, XIAP | ALDH1A1 4172/4885TSHR 3966/4885LMNA 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.